🇺🇸 FDA
Patent

US 9327023

HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 9327023 (HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue May 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K31/337, A61K31/685